MEDLINE 欄位代碼
這些兩個字元的欄位代碼可識別您透過電子郵件寄送或儲存至檔案之記錄中的欄位。
| FN |
檔案名稱
|
| VR |
版本號碼
|
| PT |
出版類型
|
| AN |
PubMed ID
|
| DT |
文件類型 (J = 期刊)
|
| TI |
標題
|
| FT |
外文標題
|
| AU |
作者
|
| CA |
公司作者
|
| SO |
來源 (卷、期、頁數、出版時間)
|
| VL |
卷冊
|
| IS |
期
|
| PS |
頁數
|
| PY |
出版年份
|
| PD |
出版日期
|
| LA |
語言
|
| AB |
摘要
|
| A2 |
其他摘要
|
| C1 |
作者地址
|
| RI |
Web of Science ResearcherID 號碼
|
| OI |
ORCID 識別碼 (Open Researcher and Contributor ID)
|
| MH |
MeSH 主題詞
|
| SS |
引用文獻子集
|
| ID |
關鍵字清單
|
| SD |
序列資料
|
| GN |
基因符號
|
| CN |
化學
|
| NM |
個人名稱主題
|
| SF |
太空飛行任務
|
| SC |
研究領域
|
| SN |
國際標準期刊號 (ISSN)
|
| U1 |
使用情況計數 (過去 180 天)
|
| U2 |
使用情況計數 (自 2013 年起)
|
| JC |
NLM 唯一 ID
|
| PA |
國家/地區
|
| GI |
授權資訊
|
| OB |
記錄擁有人
|
| SA |
狀態
|
| IV |
調查者
|
| NR |
參考文獻數
|
| RC |
建立日期、完成日期、修訂日期
|
| NO |
註解、修正、勘誤
|
| PE |
電子出版
|
| NT |
一般備註
|
| DI |
數位物件識別碼 (DOI)
|
| UT |
ISI 唯一文章識別碼
|
| OA |
Open Access 指標
|
| HP |
ESI 熱門論文。請注意，此欄位僅對 ESI 訂閱者有效
|
| HC |
ESI 被高度引用的論文。請注意，此欄位僅對 ESI 訂閱者有效
|
| DA |
此報告產生的日期
|
| ER |
[記錄結束]
|
| EF |
[檔案結束]
|
輸出記錄範例 - 儲存為 HTML 格式
|
PT
|
J
|
|
AN
|
22189395
|
|
DT
|
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
|
|
TI
|
The molecular classification of medulloblastoma: driving the next generation clinical trials.
|
|
AU
|
Leary, Sarah E S
Olson, James M
|
|
SO
|
Current opinion in pediatrics
|
|
VL
|
24
|
|
IS
|
1
|
|
PS
|
33-9
|
|
PY
|
2012
|
|
PD
|
2012 Feb
|
|
LA
|
英文
|
|
AB
|
PURPOSE OF REVIEW:Most children diagnosed with cancer today are expected to be cured.Medulloblastoma, the most common pediatric malignant brain tumor, is an example of a disease that has benefitted from advances in diagnostic imaging, surgical techniques, radiation therapy and combination chemotherapy over the past decades.It was an incurable disease 50 years ago, but approximately 70% of children with medulloblastoma are now cured of their disease.However, the pace of increasing the cure rate has slowed over the past 2 decades, and we have likely reached the maximal benefit that can be achieved with cytotoxic therapy and clinical risk stratification.Long-term toxicity of therapy also remains significant.To increase cure rates and decrease long-term toxicity, there is great interest in incorporating biologic 'targeted' therapy into treatment of medulloblastoma, but this will require a paradigm shift in how we classify and study disease.RECENT FINDINGS:Using genome-based high-throughput analytic techniques, several groups have independently reported methods of molecular classification of medulloblastoma within the past year.This has resulted in a working consensus to view medulloblastoma as four molecular subtypes, including wingless-type murine mammary tumor virus integration site (WNT) pathway subtype, Sonic Hedgehog pathway subtype and two less well defined subtypes (groups C and D).SUMMARY:Novel classification and risk stratification based on biologic subtypes of disease will form the basis of further study in medulloblastoma and identify specific subtypes that warrant greater research focus.
|
|
C1
|
Seattle Children's Hospital, University of Washington School of Medicine, Washington, USA. sarah.leary@seattlechildrens.org
|
|
SS
|
Index Medicus
|
|
SN
|
1531-698X
|
|
JC
|
9000850
|
|
PA
|
United States
|
|
GI
|
R01CA112350 / NCI NIH HHS.R01CA114567 / NCI NIH HHS
|
|
SA
|
In-Process
|
|
RC
|
16 Jan 2012
|
|
UT
|
MEDLINE:22189395
|
|
ER
|
|
|
預設輸出欄位
下列欄位為出現在「勾選的清單」頁面上的預設輸出欄位。
您可在產生您的輸出時取消選取這些欄位。
相關資訊
|
